Literature DB >> 33388357

The expanding clinical and genetic spectrum of ANO3 dystonia.

Li-Ting Jiang1, Li-Xi Li2, Ying Liu3, Xiao-Long Zhang4, You-Gui Pan5, Lin Wang6, Xin-Hua Wan7, Ling-Jing Jin8.   

Abstract

INTRODUCTION: Dystonia is a movement disorder with high clinical and genetic heterogeneity. Mutations in Anoctamin-3 (ANO3) gene have been reported to cause dystonia 24 (DYT24). This study aims to clarify the spectrum and frequency of ANO3 rare variants in Chinese populations with primary dystonia and understand the clinical and genetic features of DYT24.
METHODS: Sanger sequencing was used to screen all exons and exon-intron boundaries of ANO3 for rare variants in 115 primary dystonia patients. The clinical manifestations of patients with ANO3 variants in our study and previously reported literatures were further characterized.
RESULTS: Four distinct variants of ANO3 (c.1127A > G, c.1235 T > A, c.1531-3T > C, c.-11G > T) were identified in six unrelated individuals. Combined with our work and literature review, a total of 35 different rare variants distributed in ANO3 were identified in 62 dystonia patients. The predominant phenotype is cranio-cervical dystonia and more than half of patients develop head/limb tremor. Most of patients presented with isolated dystonia whereas few of them showed combined dystonia. The age of onset ranged from 1 to 69 years and peaked in late adulthood, while for generalized dystonia it peaked in a young age. Half of patients with generalized dystonia experienced deep brain stimulation (DBS). And all of them showed improvement of dystonia by DBS.
CONCLUSIONS: This study confirms a relatively high frequency of rare ANO3 variants in Chinese patients with dystonia and indicates that the late adulthood-onset, cranio-cervical dystonia seems to be an important feature of the ANO3 phenotype. Further functional studies are warranted to understand the role of ANO3 in dystonia.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  ANO3; Dystonia; Genotype; Phenotype; Rare variant

Mesh:

Substances:

Year:  2020        PMID: 33388357     DOI: 10.1016/j.neulet.2020.135590

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

1.  Coenzyme Q10 enhances remyelination and regulate inflammation effects of cuprizone in corpus callosum of chronic model of multiple sclerosis.

Authors:  Behnam Khalilian; Soheila Madadi; Nima Fattahi; Beheshteh Abouhamzeh
Journal:  J Mol Histol       Date:  2020-11-27       Impact factor: 2.611

Review 2.  Dystonia Diagnosis: Clinical Neurophysiology and Genetics.

Authors:  Lazzaro di Biase; Alessandro Di Santo; Maria Letizia Caminiti; Pasquale Maria Pecoraro; Simona Paola Carbone; Vincenzo Di Lazzaro
Journal:  J Clin Med       Date:  2022-07-19       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.